WO2003038032A8 - Means for inhibition of the synthesis of viral proteins - Google Patents
Means for inhibition of the synthesis of viral proteinsInfo
- Publication number
- WO2003038032A8 WO2003038032A8 PCT/DE2002/004052 DE0204052W WO03038032A8 WO 2003038032 A8 WO2003038032 A8 WO 2003038032A8 DE 0204052 W DE0204052 W DE 0204052W WO 03038032 A8 WO03038032 A8 WO 03038032A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vpr
- hiv
- immune deficiency
- inhibitors
- inhibition
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 108010067390 Viral Proteins Proteins 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 101710149136 Protein Vpr Proteins 0.000 abstract 3
- 230000007812 deficiency Effects 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 241000713666 Lentivirus Species 0.000 abstract 2
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 abstract 2
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 108010072220 Cyclophilin A Proteins 0.000 abstract 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 abstract 1
- 108090000769 Isomerases Proteins 0.000 abstract 1
- 102000004195 Isomerases Human genes 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 230000000798 anti-retroviral effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 238000011225 antiretroviral therapy Methods 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 235000013930 proline Nutrition 0.000 abstract 1
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to means for inhibition of primate lentiviruses, in particular the use of PPIase inhibitors as means for inhibiting human immune deficiency viruses type 1 and 2 (HIV-1 and HIV-2) and simian immune deficiency viruses (SIV). It can be shown using viral protein R (Vpr), that inhibitors of cellular peptidyl-prolyl cis/trans isomerases (PPIases) inhibit the expression, folding protein stability and the biological efficacy of Vpr. The anti-viral effect of PPIase inhibitors, in particular, cyclosporin A, is based on a specific interaction of PPIases, in particular of cyclophilin A, with prolines on the N-terminus of Vpr. Applications are in anti-retroviral therapy and prevention of infections with lentiviruses which cause immune deficiency in humans and animals, in particular of AIDS or HIV-induced pathological conditions, also in combination with other anti-retroviral medicaments.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20220744U DE20220744U1 (en) | 2001-10-25 | 2002-10-25 | Lentivirus inhibitor |
| AU2002347102A AU2002347102A1 (en) | 2001-10-25 | 2002-10-25 | Means for inhibition of the synthesis of viral proteins |
| EP02782752A EP1439853A2 (en) | 2001-10-25 | 2002-10-25 | Means for inhibition of lentiviruses |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10153902 | 2001-10-25 | ||
| DE10153902.9 | 2001-10-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2003038032A2 WO2003038032A2 (en) | 2003-05-08 |
| WO2003038032A8 true WO2003038032A8 (en) | 2003-08-14 |
| WO2003038032A3 WO2003038032A3 (en) | 2003-10-30 |
Family
ID=7704423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DE2002/004052 WO2003038032A2 (en) | 2001-10-25 | 2002-10-25 | Means for inhibition of the synthesis of viral proteins |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1439853A2 (en) |
| AU (1) | AU2002347102A1 (en) |
| DE (1) | DE20220744U1 (en) |
| WO (1) | WO2003038032A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10361944A1 (en) * | 2003-12-31 | 2005-07-28 | Viromics Gmbh | Agent for inhibiting virus replication by regulating protein folding |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK278808B6 (en) * | 1990-11-02 | 1998-03-04 | Novartis Ag | CYCLOSINS, THEIR USE FOR PREPARING THE TREATMENT |
| JP2000510097A (en) * | 1996-03-12 | 2000-08-08 | ザ ピコワー インスティテュート フォー メディカル リサーチ | Treatment of HIV infection by interfering with host cell cyclophilin receptor activity |
| US7108988B2 (en) * | 2001-11-02 | 2006-09-19 | The J. David Gladstone Institutes | Methods of identifying agents for inhibiting lentivirus replication |
-
2002
- 2002-10-25 WO PCT/DE2002/004052 patent/WO2003038032A2/en not_active Application Discontinuation
- 2002-10-25 EP EP02782752A patent/EP1439853A2/en not_active Ceased
- 2002-10-25 DE DE20220744U patent/DE20220744U1/en not_active Expired - Lifetime
- 2002-10-25 AU AU2002347102A patent/AU2002347102A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002347102A1 (en) | 2003-05-12 |
| WO2003038032A3 (en) | 2003-10-30 |
| WO2003038032A2 (en) | 2003-05-08 |
| EP1439853A2 (en) | 2004-07-28 |
| DE20220744U1 (en) | 2004-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE264914T1 (en) | ANTIVIRAL PROTEINS, DNA CODING THEREOF, AND USE THEREOF | |
| EA200200724A1 (en) | VACCINE FOR PREVENTION OR THERAPEUTIC IMMUNIZATION AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY (HIV) | |
| CA2217737A1 (en) | Thf-containing sulfonamide inhibitors of aspartyl protease | |
| AP1717A (en) | Sulfonamide inhibitors of aspartyl protease. | |
| WO2004096818A3 (en) | Method and compositions for identifying anti-hiv therapeutic compounds | |
| MY137777A (en) | Inhibitors of aspartyl protease | |
| MY115797A (en) | Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease | |
| BR9607625A (en) | Retroviral protease inhibitors hydroxyethylamino hydroxyethylamino amino acid heterocyclocarbonyl | |
| EP1637518A3 (en) | Inhibitors of aspartyl protease | |
| WO2007002172A3 (en) | Hiv-1 protease inhibitors | |
| WO2004029201A3 (en) | Peptide derivative fusion inhibitors of hiv infection | |
| WO2003038032A3 (en) | Means for inhibition of the synthesis of viral proteins | |
| DE60130641D1 (en) | PHARMACOLOGICALLY ACTIVE ANTIVIRAL PEPTIDES AND METHODS OF THEIR APPLICATION | |
| CA2195125A1 (en) | Difluorostatone antiviral agents | |
| WO2022125378A8 (en) | Combination therapy | |
| GR3024226T3 (en) | Antiviral naphthoquinone compounds, compositions and uses thereof. | |
| UA41338C2 (en) | METHOD OF INHIBITION OF RETROVIRUS INFECTION CAUSED BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), METHOD OF IMMUNIDUF IMMUNODE VIRUS INHIBITION | |
| WO2002034909A3 (en) | Engineered chimera of hiv protein fragments and uses thereof | |
| DK0545991T3 (en) | Peptides that block human immunodeficiency virus infections, and methods for their use | |
| AP2003002852A0 (en) | Natural antibodies active against HIV virus | |
| GB2382529A (en) | Immunomodulator for the management of human immunodficiency virus (hiv) disease/infection | |
| WO2005068492A3 (en) | Peptide inhibitors of retroviral integrase useful for the treatment of retroviral infection | |
| ZA95756B (en) | Macrocyclic difluorostatone derivatives useful as antiviral agents | |
| WO2005028442A3 (en) | 2-pyridinone derivatives, having hiv inhibiting properties | |
| EP1862471A3 (en) | Pharmacologically active antiviral peptides and methods of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| CFP | Corrected version of a pamphlet front page | ||
| CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 19/2003 UNDER (72) DELETE ""SCHUBERT, ULRICH; JENAISCHE STRASSE 51, 07407 UHLSTAEDT (DE)."" |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002782752 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002782752 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: JP |